This crossover thing does muddy the waters a bit, but I guess in Provenge's favor. Given that there is some indication of Provenge efficacy, it seems to me it would be hard to do a trial now without crossovers allowed. So, ironically, the more effective that Provenge seems to be, the harder it becomes in practice to do a rigorous trial.
Market Data 
Markets 
AI
